A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
70actual
Sites
35
Countries
Argentina, Australia, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-09 | actual | When the study began enrolling |
| Primary completion | 2025-05-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-12 | actual | The whole study's end, after follow-up |
| First posted | 2022-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: BMS-986360 — also filed as CC-90001
- Drug: Docetaxel — also filed as Taxotere®
- Drug: Nivolumab — also filed as Opdivo®, BMS-936558
- Drug: Capecitabine — also filed as Xeloda®
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Adverse Events (AEs)
measured Up to approximately 2 years
Number of participants with Serious Adverse Events (SAEs)
measured Up to approximately 2 years
Number of participants with Dose-Limiting Toxicities (DLTs)
measured Up to approximately 2 years
Number of participants with AEs leading to discontinuation
measured Up to approximately 2 years
Number of deaths
measured Up to approximately 2 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed